Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms OTIVACTO
- Sponsors Boehringer Ingelheim
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 15 May 2017 Planned End Date changed from 23 Jan 2018 to 18 Jun 2018.
- 15 May 2017 Planned primary completion date changed from 23 Jan 2018 to 18 Jun 2018.